Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the ...

Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA stock a buy?

Moderna reported mixed fourth quarter earnings and full-year 2024 earnings Friday. Moderna's stock was down 5% in premarket ...

Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...

Moderna Inc. (NASDAQ:MRNA) reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from ...

Looking ahead, BofA cut its 2025 and 2026 revenue forecasts by 18% and 15%, respectively. While negative EPS projections ...

Moderna ( MRNA) reported mixed fourth quarter earnings, and full year 2024 earnings compared to Wall Street expectations Friday. Moderna's stock was down 4.5% in pre-market trading on the earnings ...

Moderna shares fell 3% in premarket trading after the biotech company swung to a quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion, ...